Founder’s Vision
ANKTIVA
BCG
Our Science
Careers
Contact
Patients & Caregivers
ANKTIVA®
Clinical Trials
Patients
Therapeutic Areas
Bladder Cancer
Glioblastoma
HIV
Human Papillomavirus
Lymphopenia
Lynch Syndrome
Non-Hodgkin Lymphoma
Non-Small Cell Lung Cancer
Ovarian Cancer
Healthcare Providers
ANKTIVA®
Clinical Trials
Trial Investigators
Expanded Access
Researchers
Platforms & Modalities
Trial Investigators
Cell Licensing
Publications
Our Company
About
Pipeline
Contact
Compliance & Transparency
News and Events
Investors
Select Page
Acceptance Requirements
Adult patients diagnosed with CD19 and CD20-positive B-cell non-Hodgkin lymphoma
Have completed two lines of chemotherapy
Search for:
Recent Posts
LUGPA 2025 Annual Meeting
ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates
ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors
UK MHRA Approves ImmunityBio’s ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
LUGPA Regional Meeting
